Alpha 2.0
Login Register
» Authors » William W Harless

William W Harless

Explore the profile of William W Harless including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 42
Followers 0
Related Specialties
Oncology
Biochemistry
Cell Biology
Top 10 Co-Authors
Myron R Szewczuk
Bessi Qorri
Beth Lewis
Reza Bayat Mokhtari
Leili Baghaie
Abdulrahman M Yaish
Mehdi Sheikhi
Shamano Minhas
Alexander Wawer
Yunfan Li
Published In
Cells
Cancers (Basel)
BMC Cancer
Cancer Cell Int
Vaccines (Basel)
Affiliations
Soon will be listed here.
Recent Articles
1.
Novel sACE2-Anti-CD16VHH Fusion Protein Surreptitiously Inhibits SARS-CoV-2 Variant Spike Proteins and Macrophage Cytokines, and Activates Natural Killer Cell Cytotoxicity
Sheikhi A, Baghaie L, Rahbarizadeh F, Safarzadeh Kozani P, Moradian C, Davidi M, et al.
Vaccines (Basel) . 2025 Feb; 13(2). PMID: 40006745
: The SARS-CoV-2's high mutations and replication rates contribute to its high infectivity and resistance to current vaccinations and treatments. The primary cause of resistance to most current treatments aligns...
2.
Contemporaneous Perioperative Inflammatory and Angiogenic Cytokine Profiles of Surgical Breast, Colorectal, and Prostate Cancer Patients: Clinical Implications
Baghaie L, Haxho F, Leroy F, Lewis B, Wawer A, Minhas S, et al.
Cells . 2023 Dec; 12(23). PMID: 38067195
Surgery-induced tumor growth acceleration and synchronous metastatic growth promotion have been observed for decades. Surgery-induced wound healing, orchestrated through growth factors, chemokines, and cytokines, can negatively impact patients harboring residual...
3.
Novel Therapeutic Target Critical for SARS-CoV-2 Infectivity and Induction of the Cytokine Release Syndrome
Harless W, Lewis B, Qorri B, Abdulkhalek S, Szewczuk M
Cells . 2023 May; 12(9). PMID: 37174732
We discovered a novel therapeutic target critical for SARS-CoV-2, cellular infectivity and the induction of the cytokine release syndrome. Here, we show that the mammalian enzyme neuraminidase-1 (Neu-1) is part...
4.
Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases
Qorri B, Bayat Mokhtari R, Harless W, Szewczuk M
Cancers (Basel) . 2022 Jul; 14(15). PMID: 35892853
Metastatic pancreatic cancer has an invariably fatal outcome, with an estimated median progression-free survival of approximately six months employing our best combination chemotherapeutic regimens. Once drug resistance develops, manifested by...
5.
Next Generation of Cancer Drug Repurposing: Therapeutic Combination of Aspirin and Oseltamivir Phosphate Potentiates Gemcitabine to Disable Key Survival Pathways Critical for Pancreatic Cancer Progression
Qorri B, Bayat Mokhtari R, Harless W, Szewczuk M
Cancers (Basel) . 2022 Mar; 14(6). PMID: 35326525
Resistance to chemotherapeutics and high metastatic rates contribute to the abysmal survival rate in patients with pancreatic cancer. An alternate approach for treating human pancreatic cancer involves repurposing the anti-inflammatory...
6.
Cancer treatments transform residual cancer cell phenotype
Harless W
Cancer Cell Int . 2011 Jan; 11(1):1. PMID: 21214935
Background: Physiologic wound repair and tissue regeneration are associated with distinct cellular behaviors triggered by tissue damage. Normally quiescent stem cells proliferate to regenerate damaged tissue, while relatively immobile epithelial...
7.
Revisiting perioperative chemotherapy: the critical importance of targeting residual cancer prior to wound healing
Harless W
BMC Cancer . 2009 Apr; 9:118. PMID: 19383172
Background: Scientists and physicians have long noted similarities between the general behavior of a cancerous tumor and the physiological process of wound healing. But it may be during metastasis that...